B-cell chronic lymphocytic leukemia

Researchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…

This early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…

This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…

This early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…

This study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…

This phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…

This early-stage study tested an oral drug called AUR104 in 9 adults with certain blood cancers (lymphomas and leukemia) that had come back or stopped responding to treatment. The main goal was to check the drug's safety and how the body processes it. The trial was terminated ear…

This early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…

This early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…

This small Phase 2 trial tested two drugs — ibrutinib and pembrolizumab — in people with untreated high-risk chronic lymphocytic leukemia (CLL). The goal was to see if the combination could improve the body's immune function and shrink or control the cancer. However, the study wa…

This early-stage trial tested an oral drug called HMPL-523 in 69 people with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This study tested a combination of two targeted drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal was to see if the combination was safe and could shrink tumors. However, the trial was termi…

This study tested the safety and effectiveness of the drug umbralisib in 12 people with chronic lymphocytic leukemia (CLL) who had not received prior treatment. The goal was to see how many patients had their cancer shrink or disappear. The study was stopped early, but results st…

This phase II trial tested a combination of two drugs—daratumumab and ibrutinib—in people with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to treatment. The goal was to see if the combo could shrink or eliminate cancer better than ibrutinib alone. …

This study tested a two-drug combination (ibrutinib and venetoclax) in 30 adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatments. The goal was to see if starting with ibrutinib alone, then adding venetoclax, could safely clear t…

This small early-phase trial tested whether adding pirtobrutinib to venetoclax could wipe out leftover cancer cells in people with CLL/SLL who still had detectable disease after venetoclax alone. Only 3 people enrolled before the study was terminated, so we cannot draw any reliab…

This early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma,…

This early-stage study tested a new drug called JBH492 in 25 people with two types of blood cancer (chronic lymphocytic leukemia and non-Hodgkin's lymphoma) that had returned or stopped responding to standard treatments. The main goal was to check the drug's safety and find the r…

This study tested the drug ofatumumab (Arzerra) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who still had signs of disease after chemotherapy. The goal was to see if the drug could clear remaining cancer cells and keep the disease under c…

This pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…

This study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to …